Ipca Laboratories sees strong Q2/H1 FY26 financial growth

Ipca Laboratories reported a 7% rise in Standalone Net Total Income to INR 1952.24 crores for Q2 FY26, with Consolidated Net Total Income up 9% to INR 2584.36 crores. Standalone Net Profit after exceptional items grew by 25% to INR 304.74 crores, while Consolidated Net Profit increased by 23% to INR 282.57 crores. The company's EBITDA before forex, other income, and exceptional items also saw substantial growth, with Standalone EBITDA margin at 25.46% and Consolidated at 21.68% in Q2 FY26.

For the first half of FY26, Standalone Net Total Income reached INR 3724.16 crores (up 9%), and Consolidated Net Total Income was INR 4925.87 crores (up 10%). Standalone Net Profit after tax for H1 FY26 was INR 566.78 crores, marking a 26% increase, and Consolidated Net Profit after tax rose 22% to INR 515.78 crores. Export Income contributed significantly, growing 7% to INR 813.65 crores in Q2 FY26 and 12% to INR 1513.41 crores for H1 FY26.

The company noted that a provision of €19.55m for an European Commission fine was fully settled by Unichem, with INR 58.26 Crore representing the interest recorded in Q2/H1 FY26 as an exceptional item. Ipca Laboratories is a fully integrated pharmaceutical company with a strong focus on exports, producing Finished Dosage Forms and Active Pharmaceutical Ingredients.